Oct 19 (Reuters) – Hong Kong-listed Metis TechBio said on Monday it has entered into a collaboration agreement with Eli Lilly worth up to $1.1 billion to research and develop tissue-specific drug
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
VIDEO SHOWS: ARCHIVE FOOTAGE RELATING TO SENEGAL'S AFRICA CUP OF NATIONS APPEAL SHOWS: LAUSANNE, SWITZERLAND…
By Tharuniyaa Lakshmi and Ragini Mathur Oct 19 (Reuters) - The benchmark S&P 500 and…
By Andrew Goudsward WASHINGTON, Oct 19 (Reuters) - An ex-OpenAI engineer accused of planting a…
Oct 19 (OPTA) - Rankings from the WTA Tour singles Rank Points (The article has…
By Blake Brittain WASHINGTON, Oct 19 (Reuters) - The US Supreme Court rejected on Monday…
By Utkarsh Hathi Oct 19 (Reuters) - Canada's main stock index fell on Monday, dragged…